Shin Jung Hwan, Park Hyeyoung, Ehm Gwan Hee, Lee Woong Woo, Yun Ji Young, Kim Young Eun, Lee Jee-Young, Kim Han-Joon, Kim Jong-Min, Jeon Beom Seok, Park Sung-Sup
Department of Neurology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Neurology, Myongi Hospital, Goyang, Republic of Korea.
PLoS One. 2015 Aug 12;10(8):e0135275. doi: 10.1371/journal.pone.0135275. eCollection 2015.
SCA17 is an autosomal dominant cerebellar ataxia with expansion of the CAG/CAA trinucleotide repeats in the TATA-binding protein (TBP) gene. SCA17 can have various clinical presentations including parkinsonism, ataxia, chorea and dystonia. SCA17 is diagnosed by detecting the expanded CAG repeats in the TBP gene; however, in the literature, pathologic repeat numbers as low as 41 overlap with normal repeat numbers.
The subjects in this study included patients with involuntary movement disorders such as cerebellar ataxia, parkinsonism, chorea and dystonia who visited Seoul National University Hospital between Jan. 2006 and Apr. 2014 and were screened for SCA17. Those who were diagnosed with other genetic diseases or nondegenerative diseases were excluded. DNA from healthy subjects who did not have a family history of parkinsonism, ataxia, psychiatric symptoms, chorea or dystonia served as the control. In total, 5242 chromosomes from 2099 patients and 522 normal controls were analyzed.
The total number of patients included in the analysis was 2099 (parkinsonism, 1706; ataxia, 345; chorea, 37; and dystonia, 11). In the normal control, up to 44 repeats were found. In the 44 repeat group, there were 7 (0.3%) patients and 1 (0.2%) normal control. In 43 repeat group, there were 8 (0.4%) patients and 2 (0.4%) normal controls. In the 42 repeat group, there were 16 (0.8%) patients and 3 (0.6%) normal controls. In 41 repeat group, there were 48 (2.3%) patients and 8 (1.5%) normal controls. Considering the overlaps and non-significant differences in allelic frequencies between the patients and the normal controls with low-expansions, we could not determine a definitive cutoff value for the pathologic CAG repeat number of SCA17.
Because the statistical analysis between the normal controls and patients with low range expansions failed to show any differences so far, we must consider that clinical cases with low range expansions could be idiopathic movement disorders showing coincidental CAG/CAA expansions. Thus, we need to reconsider the pathologic role of low range expansions (41-42). Long term follow up and comprehensive investigations using autopsy and imaging studies in patients and controls with low range expansions are necessary to determine the cutoff value for the pathologic CAG repeat number of SCA17.
脊髓小脑共济失调17型(SCA17)是一种常染色体显性遗传性小脑共济失调,由TATA结合蛋白(TBP)基因中的CAG/CAA三核苷酸重复序列扩增引起。SCA17可有多种临床表现,包括帕金森综合征、共济失调、舞蹈症和肌张力障碍。SCA17通过检测TBP基因中扩增的CAG重复序列来诊断;然而,在文献中,低至41的病理重复数与正常重复数重叠。
本研究的受试者包括2006年1月至2014年4月间就诊于首尔国立大学医院并接受SCA17筛查的非自愿性运动障碍患者,如小脑共济失调、帕金森综合征、舞蹈症和肌张力障碍患者。排除那些被诊断患有其他遗传疾病或非退行性疾病的患者。没有帕金森综合征、共济失调、精神症状、舞蹈症或肌张力障碍家族史的健康受试者的DNA作为对照。总共分析了2099例患者的5242条染色体和522例正常对照。
纳入分析的患者总数为2099例(帕金森综合征1706例;共济失调345例;舞蹈症37例;肌张力障碍11例)。在正常对照中,发现重复数高达44。在44重复数组中,有7例患者(0.3%)和1例正常对照(0.2%)。在43重复数组中,有8例患者(0.4%)和2例正常对照(0.4%)。在42重复数组中,有16例患者(0.8%)和3例正常对照(0.6%)。在41重复数组中,有48例患者(2.3%)和8例正常对照(1.5%)。考虑到低扩增患者与正常对照之间等位基因频率的重叠和无显著差异,我们无法确定SCA17病理CAG重复数的明确临界值。
由于正常对照与低范围扩增患者之间的统计分析目前未显示任何差异,我们必须考虑低范围扩增的临床病例可能是显示巧合的CAG/CAA扩增的特发性运动障碍。因此,我们需要重新考虑低范围扩增(41 - 42)的病理作用。对低范围扩增的患者和对照进行长期随访,并使用尸检和影像学研究进行全面调查,对于确定SCA17病理CAG重复数的临界值是必要的。